Erik Harris has been promoted to executive vice president and chief commercial officer by Novato-based Ultragenyx Biopharmaceutical.
Harris joined the developer of serious rare and ultrarare genetic diseases in 2017 as senior vice president and head of North American commercial operations. In his new role, the company stated, Harris will be responsible for all commercial operations in North America, Europe and Latin America.
“Erik has proven his ability to build and lead a team that has successfully launched two rare disease treatments in North America,” said Emil D. Kakkis, M.D., Ph.D., CEO and president. “He is a strong, results-oriented leader and I’m looking forward to his continued success as he expands the scope and geographic responsibility of his role.”
Prior to Ultragenyx, Harris spent six years at Crescendo Bioscience, a subsidiary of Myriad Genetics. At Crescendo, he held various leadership positions, most recently as vice president of commercial, leading all aspects of marketing, sales, managed care and customer service. He previously was vice president of pulmonology marketing at Intermune. Earlier in his career, he held positions in the commercial organizations at Elan Pharmaceuticals, Genentech and Bristol-Myers Squibb Company.
Harris served as a lieutenant commander in naval aviation and a Congressional fellow for the Navy. He received his MBA at the Wharton School of Business, and Bachelor of Science at the United States Naval Academy.
Ultragenyx is traded on the Nasdaq exchange under the ticker symbol "RARE."